Biotechnology
Our team regularly advises clients developing biotech products in areas including biotechnology derived proteins (such as insulin), immunologicals (such as vaccines and allergens), blood or plasma derived products, and engineered tissues.
Our team benefits from having several members of the group who have completed degrees in subjects including molecular biology, biochemistry and genetics. This knowledge enables us to quickly grasp technical concepts and provide nuanced and tailored advice.
We closely follow new developments and emerging trends in the biotech market. For example, we have been following the emerging regulatory pathways for biosimilars and advising clients on appropriate strategies.
We have worked with many well-known companies on their biological products, including Pfizer, Novartis, Regeneron, Amgen and Roche.
Explore our sectors
Meet our lawyers
News and insights
Publications: 10 June 2022
The selection of a patent for Patent Term Extension (PTE) or Supplementary Protection Certification (SPC) exclusivities is a critical decision for new drug products.
Publications: 09 June 2022
Since the Supreme Court’s seminal decision in Actavis, brand and generic drug companies have been working within the antitrust framework laid out in that decision to craft patent litigation…
Blog Post: 23 March 2022
New decisions in Europe and the US in CRISPR/Cas9 patent dispute
CRISPR/Cas technology, also known as “genetic scissor”, is one of the most targeted and promising tools in gene technology. It allows targeted and extremely precise modification of the DNA in humans,…
Publications: 15 December 2020
Healthcare accent is on smaller deals
Transactions in the U.S. healthcare space rebounded in autumn, although with a greater proportion of smaller deals than in recent years.
Download our sector brochure
